BIA response to Biological Security Strategy call for evidence

Touchlight’s dbDNA technology is the first synthetic DNA technology to receive a GMP certificate globally.

Oxford Drug Design, the AI drug discovery company, has successfully completed additional in vivo validation in its potential first-in-class approach against multiple tumours.

J.P. Morgan Healthcare Conference 2025: Genomics announces Dr. Jose-Carlos Gutiérrez-Ramos as new board member to accelerate global expansion and life sciences R&D growth.

Excelra has partnered with Orogen Therapeutics, an innovative DNA-Encoded Library (DEL) and AI-driven biotechnology company currently developing a portfolio of best-in-class small molecule treatments.

In a new report, Concr team describe a ‘critical imbalance’ in a research and funding landscape where ‘other’ cancers are left in the dark.

New legislation was laid in Parliament last Thursday to modernise the regulation of clinical trials in the UK.